Our Work
Leading the Industry in Therapeutic Development Programs and Innovative Drug Delivery Systems
Our 3 Pillar Strategy
Novel Drug Discovery Platform
API Modification
Develop new API’s via selective modifications of tryptamine and phenethylamine-based scaffolds specifically to alter their pharma cokinetics without modifying their therapeutic potential.
Modifications involve replacing selective hydrogens with deuterium atoms.
Optimizing unique physicochemical attributes e.g. salts, crystal forms, co-crystals, etc.
Proprietary Drug Delivery Systems
Research and Development
Efficient delivery system that attempts to bypass the liver metabolism with a direct path to the brain providing a faster onset.
Modified-release formulations with the potential to reduce side effects and to control exposure.
Dose control through proprietary device platform.
Delivery systems may be applied to many psychedelic compounds.
Innovative Treatment Regimen
Science Meets Technology
Software-based platform to gather clinical research data from psychedelic treatment.
EMBARK six domain best-practices psychotherapy program designed to provide consistent therapist training and consistent psychotherapy delivery in clinical trials.
Patents
15 patent filings cover a wide range of novel psychedelic compounds from different classes, including targeted structural modifications to improve the drug pharmacokinetic characteristics and safety profiles without altering their receptor binding. Novel drug delivery platform claims are expected to enable administration of the psychedelic drugs with faster onset of action, higher bioavailability by way of bypassing the liver metabolism and expected to offer more control for better patient experience and optimized therapeutic outcomes.
Advancing Mental Healthcare Through Evidence Based Therapeutics
CYB001
PHASE IIA & PHASE IIB CLINICAL TRIAL
SUBLINGUAL PSILOCYBIN IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD)
PHASE IIA
Randomized Parallel Group Open Label BE Study
PSILOCYBIN (PY)
PHASE IIB
Randomized Double Blind Placebo Controlled Safety & Efficacy Study
MDD patients with moderate depression (MADRS score 18-34)
Primary efficacy in 30 days
Patients will be followed for 4 months for safety and efficacy
Duration: approx 12 months
Clinical trial will adhere to ICH and GCP guidelines, with the aim to utilize clinical data in jurisdictions such as USA, Canada and Europe.
Research and Development Pipeline
PROGRAM
- DISCOVERY
- PRECLINICAL
- PHASE I
- PHASE II
- PHASE III
- REGISTRATION
Major Depressive Disorder
CYB003 - Deuterated Psilocybin Analog
PRECLINICAL
Alcohol Use Disorder
CYB003 - Deuterated Psilocybin Analog
PRECLINICAL
Anxiety Disorders
CYB004 - Deuterated Tryptamine
PRECLINICAL
Psychiatry/Neurology
CYB005 - Phenethylamines
DISCOVERY
